ArticleInternational journal of molecular sciences2025
Genomic Size Is Critical to Guarantee the Genomic Stability of Non-Replicative HSV1 Vectors.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-replicative herpes simplex virus type 1 (nrHSV-1) vectors are promising delivery vehicles for gene therapy due to their large DNA payload capacity and ability to infect a broad range of cell types. However, the genomic deletions made to generate such nrHSV-1 vectors can result in undersized genomes that trigger genomic instability-including rearrangements and size extensions-compromising their therapeutic potential. This study investigates the stabilization of undersized nrHSV-1 vectors through the insertion of stuffer DNA segments. We assess genomic stability, productivity, toxicity, and transgene expression in vitro and in vivo. Our findings demonstrate that nrHSV-1 can accommodate variations in genome size up to 5-6% and highlight the importance of maintaining a genome size close to that of the wild-type HSV-1 for enhanced genomic stability and sustained transgene expression without adverse effects. This strategy offers a promising approach for optimizing nrHSV-1 vectors for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.